Balpreet Kaur1, Isaac Perea-Gil1,2, Ioannis Karakikes3,4. 1. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA. 2. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA. 3. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA. ioannis1@stanford.edu. 4. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA. ioannis1@stanford.edu.
Abstract
PURPOSE OF REVIEW: This review describes the recent progress in nuclease-based therapeutic applications for inherited heart diseases in vitro, highlights the development of the most recent genome editing technologies and discusses the associated challenges for clinical translation. RECENT FINDINGS: Inherited cardiovascular disorders are passed from generation to generation. Over the past decade, considerable progress has been made in understanding the genetic basis of inherited heart diseases. The timely emergence of genome editing technologies using engineered programmable nucleases has revolutionized the basic research of inherited cardiovascular diseases and holds great promise for the development of targeted therapies. The genome editing toolbox is rapidly expanding, and new tools have been recently added that significantly expand the capabilities of engineered nucleases. Newer classes of versatile engineered nucleases, such as the "base editors," have been recently developed, offering the potential for efficient and precise therapeutic manipulation of the human genome.
PURPOSE OF REVIEW: This review describes the recent progress in nuclease-based therapeutic applications for inherited heart diseases in vitro, highlights the development of the most recent genome editing technologies and discusses the associated challenges for clinical translation. RECENT FINDINGS: Inherited cardiovascular disorders are passed from generation to generation. Over the past decade, considerable progress has been made in understanding the genetic basis of inherited heart diseases. The timely emergence of genome editing technologies using engineered programmable nucleases has revolutionized the basic research of inherited cardiovascular diseases and holds great promise for the development of targeted therapies. The genome editing toolbox is rapidly expanding, and new tools have been recently added that significantly expand the capabilities of engineered nucleases. Newer classes of versatile engineered nucleases, such as the "base editors," have been recently developed, offering the potential for efficient and precise therapeutic manipulation of the human genome.
Entities:
Keywords:
Base editing; CRISPR/Cas9; Cardiovascular diseases; Genome editing
Authors: Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach Journal: Science Date: 2015-12-31 Impact factor: 47.728
Authors: Ioannis Karakikes; Vittavat Termglinchan; Diana A Cepeda; Jaecheol Lee; Sebastian Diecke; Ayal Hendel; Ilanit Itzhaki; Mohamed Ameen; Rajani Shrestha; Haodi Wu; Ning Ma; Ning-Yi Shao; Timon Seeger; Nicole Woo; Kitchener D Wilson; Elena Matsa; Matthew H Porteus; Vittorio Sebastiano; Joseph C Wu Journal: Circ Res Date: 2017-02-28 Impact factor: 17.367
Authors: Janice S Chen; Yavuz S Dagdas; Benjamin P Kleinstiver; Moira M Welch; Alexander A Sousa; Lucas B Harrington; Samuel H Sternberg; J Keith Joung; Ahmet Yildiz; Jennifer A Doudna Journal: Nature Date: 2017-09-20 Impact factor: 49.962
Authors: Johnny H Hu; Shannon M Miller; Maarten H Geurts; Weixin Tang; Liwei Chen; Ning Sun; Christina M Zeina; Xue Gao; Holly A Rees; Zhi Lin; David R Liu Journal: Nature Date: 2018-02-28 Impact factor: 49.962